EFPIA On How To Make Cross-Country Collaborations Work

Cross-country collaboration on pricing and reimbursement will only work if they are based on certain overarching principles, says the European Federation of Pharmaceutical Industries and Associations.

Puzzle
EFPIA Offers Advise On Making Cross-country Collaborations Work • Source: Shutterstock

A new trend of cross-country collaborations on pricing and reimbursement in Europe seems to be taking off, but these potentially transformative initiatives will only work if they abide by certain principles, says the European Federation of Pharmaceutical Industries and Associations. Such collaborations must improve access to medicines, avoid duplication and delay, and be voluntary, EFPIA advises.

The federation points to initiatives that have joined or are seeking to join forces to improve access to medicines, such...

More from Europe

EU’s Life Sciences Strategy Faces Race Against Time, Says Clinical Trials Community

 
• By 

The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.

US Tariffs And The EU’s Critical Medicines Act: Lessons On Nearshoring And CMO Diversification

 

Nearshoring production and diversifying contract manufacturing networks can help companies stave off cost increases that will be reflected in higher medicine prices.

EMA Poised To Decide On Fate Of Lilly’s Kisunla And PharmaMar’s Aplidin In EU

 
• By 

Eli Lilly and PharmaMar were set to make their case before the European Medicines Agency this week as part of re-examination procedures for their respective drugs Kisunla and Aplidin.

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda

 
• By 

The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.

More from Geography

EU’s Life Sciences Strategy Faces Race Against Time, Says Clinical Trials Community

 
• By 

The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.

Quotable: Top Experts On Policy Hot Topics

 

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Leqembi Facing 15% Price Cut In Japan

 
• By 

Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.